Skip to main content
Clinical Trials/EUCTR2012-005329-56-DK
EUCTR2012-005329-56-DK
Active, not recruiting
Not Applicable

A phase ll trial of combination chemotherapy with intravenous oxaliplatin combined with tablet capecitabin in patients with recidivant breastcancer - capox

Dept of oncology0 sites50 target enrollmentMay 16, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
breastcancer with metastases
Sponsor
Dept of oncology
Enrollment
50
Status
Active, not recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 16, 2013
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
Dept of oncology

Eligibility Criteria

Inclusion Criteria

  • Informed concent Age \> 18 years
  • Performance status 0\-1; expected survival \> 3 months
  • Prior treatment with a Taxane and antracyclin
  • No treatment with capecitabine and oxaliplatin
  • Evaluable disease (recist 1\.1\)
  • neu granulocytes \> 1,5, thrombocytes \>100
  • bilirubine \<2 x UNL
  • Creatinine\-clearence \>30 ml/min
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • History of chemotherapy within the 4\-week period prior to the start of
  • trial medication
  • Other current or prior malignant disease except adequately treated
  • and cured carcinoma in situ of the cervix or squamous cell carcinoma of
  • Previous treatment with oxaliplatin
  • Cytotoxic or experimental treatment within a 14 days period before
  • start of trial medication
  • Current participation in other clinical trials
  • Any clinical symptoms suggesting peripheral neuropathy grade 2 or
  • CNS metastases (In case of clinical suspicion on CNS metastases a MR or

Outcomes

Primary Outcomes

Not specified

Similar Trials